cullinan therapeutics inc - CGEM
CGEM
Close Chg Chg %
11.14 -0.24 -2.15%
Closed Market
10.90
-0.24 (2.15%)
Volume: 745.98K
Last Updated:
Jan 9, 2026, 4:00 PM EDT
Company Overview: cullinan therapeutics inc - CGEM
CGEM Key Data
| Open $11.29 | Day Range 10.74 - 11.60 |
| 52 Week Range 5.68 - 13.33 | Market Cap $646.29M |
| Shares Outstanding 59.08M | Public Float 39.09M |
| Beta -0.09 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.68 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 957.62K |
CGEM Performance
| 1 Week | 7.71% | ||
| 1 Month | -8.56% | ||
| 3 Months | 47.30% | ||
| 1 Year | -2.59% | ||
| 5 Years | -68.93% |
CGEM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About cullinan therapeutics inc - CGEM
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM At a Glance
Cullinan Therapeutics, Inc.
One Main Street
Cambridge, Massachusetts 02142
| Phone | 1-617-410-4650 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -167,383,000.00 | |
| Sector | Health Technology | Employees | 111 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CGEM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.207 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.313 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.008 |
CGEM Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,507,954.955 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CGEM Liquidity
| Current Ratio | 13.53 |
| Quick Ratio | 13.53 |
| Cash Ratio | 13.018 |
CGEM Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -30.227 |
| Return on Equity | -32.065 |
| Return on Total Capital | -28.251 |
| Return on Invested Capital | -31.973 |
CGEM Capital Structure
| Total Debt to Total Equity | 0.364 |
| Total Debt to Total Capital | 0.363 |
| Total Debt to Total Assets | 0.346 |
| Long-Term Debt to Equity | 0.144 |
| Long-Term Debt to Total Capital | 0.143 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cullinan Therapeutics Inc - CGEM
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | 18.94M | - |
Sales Growth
| - | - | - | -100.00% | - |
Cost of Goods Sold (COGS) incl D&A
| 53.00K | 93.00K | 310.00K | 306.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 53.00K | 93.00K | 310.00K | 306.00K | |
Depreciation
| - | - | 310.00K | 306.00K | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| -14.52% | +75.47% | +233.33% | -1.29% | |
Gross Income
| 18.89M | (93.00K) | (310.00K) | (306.00K) | |
Gross Income Growth
| +30,567.74% | -100.49% | -233.33% | +1.29% | |
Gross Profit Margin
| - | - | - | +99.72% | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 86.84M | 132.04M | 190.34M | 196.61M | |
Research & Development
| 57.75M | 91.95M | 148.16M | 142.90M | |
Other SG&A
| 29.09M | 40.10M | 42.18M | 53.71M | |
SGA Growth
| +44.08% | +52.05% | +44.15% | +3.30% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 440.00K | - |
EBIT after Unusual Expense
| (67.95M) | (132.14M) | (191.09M) | (196.92M) | |
Non Operating Income/Expense
| 469.00K | 283.45M | 21.87M | 29.46M | |
Non-Operating Interest Income
| 477.00K | 6.61M | 21.63M | 29.66M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (67.48M) | 151.32M | (169.22M) | (167.46M) | |
Pretax Income Growth
| -13.50% | +324.22% | -211.83% | +1.04% | |
Pretax Margin
| - | - | - | -356.25% | - |
Income Tax
| - | 42.12M | (14.12M) | 117.00K | |
Income Tax - Current - Domestic
| - | - | (14.12M) | 117.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (67.48M) | 109.19M | (155.10M) | (167.57M) | |
Minority Interest Expense
| (1.92M) | (2.02M) | (1.94M) | (192.00K) | |
Net Income
| (65.57M) | 111.21M | (153.16M) | (167.38M) | |
Net Income Growth
| -26.59% | +269.61% | -237.72% | -9.28% | |
Net Margin Growth
| - | - | - | -346.14% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (65.57M) | 111.21M | (153.16M) | (167.38M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (65.57M) | 111.21M | (153.16M) | (167.38M) | |
EPS (Basic)
| -1.4804 | 2.4624 | -3.6862 | -3.1129 | |
EPS (Basic) Growth
| -24.37% | +266.33% | -249.70% | +15.55% | |
Basic Shares Outstanding
| 44.29M | 45.16M | 41.55M | 53.77M | |
EPS (Diluted)
| -1.4804 | 2.3845 | -3.6862 | -3.1129 | |
EPS (Diluted) Growth
| -24.37% | +261.07% | -254.59% | +15.55% | |
Diluted Shares Outstanding
| 44.29M | 46.64M | 41.55M | 53.77M | |
EBITDA
| (67.90M) | (132.04M) | (190.34M) | (196.61M) | |
EBITDA Growth
| -12.66% | -94.47% | -44.15% | -3.30% | |
EBITDA Margin
| - | - | - | -358.45% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 29.30 | |
| Number of Ratings | 11 | Current Quarters Estimate | -0.845 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -3.028 | |
| Last Quarter’s Earnings | -0.82 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.545 | Next Fiscal Year Estimate | -2.645 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 10 | 7 |
| Mean Estimate | -0.85 | -0.82 | -3.03 | -2.65 |
| High Estimates | -0.71 | -0.36 | -2.14 | -0.81 |
| Low Estimate | -0.95 | -0.97 | -3.86 | -3.43 |
| Coefficient of Variance | -10.77 | -25.39 | -22.71 | -37.33 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 11 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Cullinan Therapeutics Inc - CGEM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cullinan Therapeutics Inc - CGEM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 28, 2025 | Nadim Ahmed President and CEO; Director | 430,621 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.53 per share | 3,673,197.13 |
| Feb 28, 2025 | Jennifer Michaelson Chief Scientific Officer | 142,004 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.53 per share | 1,211,294.12 |
| Feb 28, 2025 | Jacquelyn Sumer Chief Legal Officer | 136,895 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.53 per share | 1,167,714.35 |
| Feb 28, 2025 | Jeffrey Jones Chief Medical Officer | 174,164 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.53 per share | 1,485,618.92 |
| Feb 24, 2025 | Mary Kay Fenton Chief Financial Officer | 60,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Mary Kay Fenton Chief Financial Officer | 120,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Nadim Ahmed President and CEO; Director | 360,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Corinne Savill Chief Business Officer | 240,990 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Corinne Savill Chief Business Officer | 75,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Jennifer Michaelson Chief Scientific Officer | 100,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Jacquelyn Sumer Chief Legal Officer | 100,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Jeffrey Jones Chief Medical Officer | 130,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |